PALB2 and breast cancer: There is also an immense increased risk of PDAC associated with germline mutation of ovarian and breast cancers (PALB2 and BRCA1/BRCA2, respectively), as alterations in germline BRCA and PALB2 are detected in approximately 5–9% of patients with PDAC and can lead to homologous repair deficiency (HRD) [15].